Robert Aaronson, MD
Pulmonary Disease · Tucson, AZNPI 1346247657
Payments from drug & device makers
Across 121 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$340
- Boehringer Ingelheim$238
- Amgen$197
- AstraZeneca$193
- Insmed, Inc.$187
- Jazz Pharmaceuticals Inc.$182
- plus $2K from 25 others
What the payments were for
- Food & beverage$2,81499%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 21 | $340 |
| Boehringer Ingelheim | 10 | $238 |
| Amgen | 9 | $197 |
| AstraZeneca | 5 | $193 |
| Insmed, Inc. | 9 | $187 |
| Jazz Pharmaceuticals Inc. | 9 | $182 |
| Harmony Biosciences LLC | 3 | $181 |
| Electromed, Inc. | 16 | $174 |
| Edwards Lifesciences | 1 | $147 |
| Abbott | 1 | $133 |
| Abiomed | 1 | $114 |
| Amarin Pharma, Inc. | 1 | $83 |
| Actelion Pharmaceuticals US, Inc. | 4 | $78 |
| Genentech USA, Inc. | 4 | $74 |
| Mylan Specialty L.p. | 3 | $58 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Tactile Systems Technology Inc | 2 | $44 |
| Novartis | 2 | $43 |
| Baxter Healthcare | 2 | $38 |
| Verona Pharma, Inc. | 1 | $34 |
| Vapotherm Inc | 1 | $33 |
| Merck | 2 | $25 |
| Johnson & Johnson | 2 | $25 |
| Grifols USA, LLC | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Viatris Specialty LLC | 1 | $22 |
| Sanofi | 1 | $20 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $17 |
| Pulmonx Corporation | 1 | $15 |
| Apria Healthcare LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PASCAL$147
- DRAGONFLY OPSTAR$133
- Wakix$125
- Impella$114
How this compares
$2,856 in reported general payments places this provider in the 50th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 46 | $594,167 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 181 | $206,572 |
| TezspireTezepelumab-Ekko | 44 | $191,782 |
| NucalaMepolizumab | 37 | $136,519 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $116,107 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 88 | $82,506 |
| Spiriva RespimatTiotropium Bromide | 82 | $67,809 |
| Dupixent SyringeDupilumab | 15 | $66,236 |
| Breo ElliptaFluticasone/Vilanterol | 102 | $54,146 |
| Dupixent PenDupilumab | 12 | $52,955 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 81 | $46,516 |
| SymbicortBudesonide/Formoterol Fumarate | 56 | $21,709 |
| Incruse ElliptaUmeclidinium Bromide | 49 | $21,423 |
| Spiriva HandihalerTiotropium Bromide | 22 | $18,638 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $14,017 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $238 | $675,993146 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $340 | $473,465467 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $193 | $295,997188 claims |
| Grifols USA, LLCProlastin C | $24 | $116,10712 claims |
| MerckDulera | $25 | $7,54616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Tucson
- Sachin ChaudharyTucson$1.2M
- Abhinav MittalTucson$570K
- Todd LocherTucson$243K
- Christian BimeTucson$175K
- Ravi ChandranTucson$92K
- Billie BixbyTucson$72K
- Swathy PuthalapattuTucson$64K
- Muhammad SalimChandler$5.9M
- Vikas SayalBullhead City$3.7M
- David BaratzPhoenix$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.